Studying Stem Cells in Menstrual Blood of Women With Endometriosis
Compares stem cells in menstrual blood from women with and without endometriosis.
Plain-language title generated from the registry record
Registry title: MEN-ENDO: Menstrual Stem Cells in Endometriosis
Key facts
- Where
- Reus and Tarragona, SpainSee the 2 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 45 years old?
Source: NCT07578480, who can take part
Where in Spain
- Universitat Rovira i Virgili. Facultat de Medicina i Ciències de la SalutReus, SpainNo longer taking part
- Hospital Universitari Joan XXIIITarragona, SpainTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Francisco Algaba Chueca
- Trial code
- NCT07578480
- Record updated
- 11 May 2026
- Original description
Endometriosis is a chronic inflammatory condition characterized by the presence of endometrium-like tissue outside the uterine cavity. It is estimated to affect approximately 10% of women of reproductive age and it is associated with chronic pelvic pain and infertility, among other symptoms.Read full original descriptionShow less
Study of the Role of Menstrual Blood-derived Stem Cells and the Immune Environment in Endometriosis
Endometriosis is a chronic inflammatory condition characterized by the presence of endometrium-like tissue outside the uterine cavity. It is estimated to affect approximately 10% of women of reproductive age and it is associated with chronic pelvic pain and infertility, among other symptoms.
Endometriosis involves complex changes in the body's cells and immune response. For this reason, the goal of this observational study is to characterize the functional, molecular, and immunological alterations in menstrual blood-derived stem cells (MenSCs) and differentiated decidual stromal cells in women with endometriosis; to validate these findings in endometrial tissue and endometriomas; and to establish their correlation with clinical parameters, with the aim of identifying key pathogenic mechanisms and potential therapeutic targets.
The main questions it aims to answer are:
* Are there functional and molecular changes in MenSCs from patients with endometriosis compared to healthy volunteers? * Are there any variations in the immune properties of MenSCs throughout the menstrual bleeding period in patients with endometriosis compared to healthy volunteers? * Are these changes also present in endometrial tissue and endometrioma samples? * Can these changes be correlated with clinical parameters in patients with endometriosis? * Can MenSCs serve as a potential therapeutic target for endometriosis?
Some participants will be asked to provide menstrual blood on a single day, while others will provide samples during the first five days of menstruation. Additionally, all participants will answer questionnaires about their diet, physical activity, stress, and pain levels. Therefore, the study does not involve the evaluation of a specific intervention on the participants.
The results will enable the identification of key altered mechanisms and potential therapeutic targets, thereby contributing to the development of more effective strategies for the diagnosis and treatment of the disease.
Inclusion: 18-45 years; Endometriosis group: Women with clinical and/or ecographical diagnostic of endometriosis; Control group: Women with the endometriosis diagnosis.
Exclusion: Diagnosis of prior chronic pelvic inflammatory or autoimmune disease; Hormonal therapy use in the previous 3 months; Use of immunosuppressants or corticosteroids in the previous 3 months; Systemic antibiotics use in the previous 3 months; History of active gynecological cancer; Positive for human immunodeficiency virus (HIV) or human papillomavirus (HPV); <18 years or >45 years; Pregnancy or lactation; Insufficient menstrual flow to allow the MenSCs isolation.